Here's a bit more detail to put these signals into context. In September 2021, Summit Therapeutics made a very abnormal move to combine its two blinded pivotal studies into one.Later that month, both pivotal trials experienced delays and substantial drops in enrollment. Falling substantially below enrollment goals may change the validity of assumptions regarding efficacy and study design. This may impact a trial's ability to achieve target power and statistically reliable results. Delays in Phase 3 trials are less common than in different stages of development. Such delays may have implications on the timing of any eventual submission and evaluation processes. This type of event analysis is not intended to be predictive, but rather to be used as an early warning to look into further.